Genprex, Inc. (GNPX) NASDAQ
0.73
-0.0169(-2.25%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.73
-0.0169(-2.25%)
Currency In USD
Address
3300 Bee Cave Road
Austin, TX 78746
United States of America (the)
Phone
877 774 4679
Website
Sector
Healthcare
Industry
Biotechnology
Employees
15
First IPO Date
March 29, 2018
| Name | Title | Pay | Year Born |
| Ryan Confer | President, Chief Executive Officer, Chief Financial Officer & Director | 638,421 | 1982 |
| Mark S. Berger | Chief Medical Officer | 631,319 | 1955 |
| David Schloss | Senior Vice President of Human Resources | 0 | N/A |
| Jack A. Roth | Chairman of Scientific & Medical Advisory Board | 0 | N/A |
| Suzanne Thornton-Jones | Senior Vice President of Regulatory Affairs & Quality | 0 | N/A |
| Greg Jancarik | Senior Director & Corporate Controller | 0 | N/A |
| Thomas C. Gallagher | Senior Vice President of Intellectual Property & Licensing | 0 | N/A |
| Celina Laney | Chief of Staff | 0 | N/A |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.